InspireMD, Inc. (NSPR)

InspireMD is a cash-burning, pre-profitability medical-device maker now in acute distress: its own filings carry substantial going-concern doubt (auditor-flagged), its flagship US product CGuard Prime was voluntarily recalled in May 2026 (customer credits and an inventory impairment pushed Q2 2026 gross margin negative), and Nasdaq has issued a minimum-bid-price deficiency notice with a reverse split under consideration. With about $30.4M of cash against a widening ~$9M-plus per quarter operating burn, the company states it lacks 12 months of funding, so a dilutive raise is effectively unavoidable. Growth is the one bright spot (H1 2026 revenue +56%, international +21%) and insiders bought stock in May 2026, but the distress overhang dominates: this is a speculative situation with meaningful risk of permanent capital loss, not an investment-quality setup.

Going-concern / auditor doubt (FY2025 10-K substantial-doubt paragraph with auditor explanatory language; Q2 2026 10-Q states insufficient resources for 12 months) fires the severe red-flag cap, dominating a neutral-to-negative tape (scoring-window polarity ≈ -0.03 on the Q2 revenue miss, $14.3M net loss and recall digestion) whose sole offset is a low-weight Zacks Buy upgrade; delta flat-to-mildly-negative vs. a mixed baseline, retail indeterminate, legal screen clean. Severe red-flag cap applied (going-concern / auditor doubt); a moderate conflicting-signals flag (bearish earnings vs. bullish sell-side upgrade) is also present but subsumed.

Short-term trend and momentum are improving (price above SMA20/SMA50, EMA9/21 stacked above price, MACD crossed positive mid-August, ADX 54 signaling a strong up-trend on the short frame), but the stock remains ~37% below its SMA200 in a long-term downtrend, trades under $100K of dollar volume per day, and both upstream override gates fail (fundamentalScore 1, qualitativeScore 1). A bullish trade plan is not permitted regardless of the chart.